iCell Gene Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

iCell Gene Therapeutics General Information

Description

Developer of gene therapeutics technology designed to target and destroy multiple types of cancer. The company's chimeric antigen receptor-engineered cells eradicate devastating diseases by entering the clinical study directed against T-cell malignancies by creating novel immunotherapies for cancer treatment, enabling patients with resistant cancer to get cost-effective cures.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 25 Health Sciences Drive
  • Suite 118, Stony Brook
  • Brookhaven, NY 11790
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 25 Health Sciences Drive
  • Suite 118, Stony Brook
  • Brookhaven, NY 11790
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iCell Gene Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view iCell Gene Therapeutics’s complete valuation and funding history, request access »

iCell Gene Therapeutics Patents

iCell Gene Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4626926-A2 Engineered immune cells for treating disorders, compositions and methods thereof Pending 28-Nov-2022
US-20240350632-A1 Engineered immune cells for treating disorders, compositions and methods thereof Pending 28-Nov-2022
WO-2024118559-A2 Engineered immune cells for treating disorders, compositions and methods thereof Inactive 28-Nov-2022
WO-2024118559-A3 Engineered immune cells for treating disorders, compositions and methods thereof Inactive 28-Nov-2022
WO-2022076256-A1 Engineered immune cells for immunotherapy using endoplasmic retention techniques Inactive 05-Oct-2020 A61K40/4224
To view iCell Gene Therapeutics’s complete patent history, request access »

iCell Gene Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iCell Gene Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Long Island High Technology Incubator Accelerator/Incubator
To view iCell Gene Therapeutics’s complete investors history, request access »

iCell Gene Therapeutics FAQs

  • When was iCell Gene Therapeutics founded?

    iCell Gene Therapeutics was founded in 2014.

  • Where is iCell Gene Therapeutics headquartered?

    iCell Gene Therapeutics is headquartered in Brookhaven, NY.

  • What is the size of iCell Gene Therapeutics?

    iCell Gene Therapeutics has 11 total employees.

  • What industry is iCell Gene Therapeutics in?

    iCell Gene Therapeutics’s primary industry is Drug Discovery.

  • Is iCell Gene Therapeutics a private or public company?

    iCell Gene Therapeutics is a Private company.

  • What is iCell Gene Therapeutics’s current revenue?

    The current revenue for iCell Gene Therapeutics is .

  • Who are iCell Gene Therapeutics’s investors?

    Long Island High Technology Incubator has invested in iCell Gene Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process